|Table of Contents|

Significance of LILRB1 and LILRB4 in the diagnosis of monocyte-differentiated acute myeloid leukemia

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 24
Page:
4582-4586
Research Field:
Publishing date:

Info

Title:
Significance of LILRB1 and LILRB4 in the diagnosis of monocyte-differentiated acute myeloid leukemia
Author(s):
RAO Ruo1; WANG Shuwen1; WU Lifang1; WANG Zhaoliang1; TANG Ruimei2; LIN Hui3
1.Clinical Laboratory;2.Department of Hematology;3.Department of Anesthesiology,Hainan General Hospital,Hainan Affiliated Hospital of Hainan Medical University，Hainan Haikou 570311,China.
Keywords:
LILRB1; LILRB4; acute myeloid leukemia; monocytic differentiation; flow cytometry
PACS:
R733.71
DOI:
10.3969/j.issn.1672-4992.2023.24.018
Abstract:
Objective:To explore the significance of LILRB1 and LILRB4 in the diagnosis of monocyte-differentiated acute myeloid leukemia (M-AML).Methods:Flow cytometry with direct immunofluorescence staining was used to detect the expression of LILRB1,LILRB4,CD64 and CD14 of 109 acute leukemia patients.Results:There was statistical difference in the positive rate of LILRB1 among M-AML,NM-AML and ALL(81.6%,0,27.3%，P＜0.01).The positive rate of M-AML group was significantly higher than that of NM-AML group and ALL group,and the positive rate of ALL group was significantly higher than that of NM-AML group.The positive rate of LILRB4 in M-AML group was 81.6% （31/38）,but LILRB4 was not expressed in both NM-AML and ALL groups(0/49,0/22),which has statistical difference(P＜0.01).The sensitivity of individual detection of LILRB1 and LILRB4 in diagnosing M-AML was 81.6%,while the sensitivity of combined detection was 86.8%,and the specificity was 100%,which was better than CD64（86.8%，61.2%）,CD14（31.6%,100%）.Conclusion:Both LILRB1,LILRB4 alone or in combination have high sensitivity and specificity for detecting M-AML,which can be used as new indicators for the diagnosis of M-AML.

References:

［1］ DOZZO A,GALVIN A,SHIN JW,et al.Modelling acute myeloid leukemia (AML):What's new? A transition from the classical to the modern［J］.Drug Delivery and Translational Research,2023,13(8):2110-2141.
［2］ KANTARJIAN H,KADIA T,DINARDO C,et al.Acute myeloid leukemia:current progress and future directions［J］.Blood Cancer Journal,2021,11(2):1-25.
［3］ KHOURY JD,SOLARY E,ABLA O，et al.The 5th edition of the world health organization classifification of haematolymphoid tumours:myeloid and histiocytic/dendritic neoplasms［J］.Leukemia,2022,36(7):1-17.
［4］ 吕国庆,张肖肖,吴隼,等.急性单核细胞白血病的临床特点及预后分析［J］.现代肿瘤医学，2022,30（17）：3199-3203. LV GQ,ZHANG XX,WU S,et al.Anolysis of clinical features and prognostic factors of acute monocytic leukemin［J］.Modern Oncology,2022,30（17）：3199-3203.
［5］ DENG M,GUI X,KIM J,et al.LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration［J］.Nature,2018,562(7728):605-609.
［6］ DOBROWOLASKA H,GILL KZ,SERBAN G,et al.Expression of immune inhibitory receptor ILT3 in acute myeloid leukemia with monocytic differentiation［J］.Cytometry B Clinical Cytometry,2013,84(1):21-29.
［7］ BENE MC,CASTOLDI G,KNAPP W,et al.Proposals for the immunological classification of acute leukemias.European Group for the Immunological Characterization of Leukemias (EGIL)［J］.Leukemia,1995,9(10):1783-1786.
［8］ EMBABY A,FATHY A,AL-AKKAD M,et al.Initial absolute monocyte count as an immune biomarker for clinical response in acute myeloid leukemia with monocytic differentiation［J］.Journal of the Egyptian National Cancer Institute,2020,32(1):1-11.
［9］ 白峰岩,王学博,赵方,等.儿童急性髓系白血病(M4/M5亚型)系统治疗的临床效果及预后因素分析［J］.实用癌症杂志,2022,37(1):154-156. BAI FY,WANG XB,ZHAO F,et al.Analysis of clinical effect and prognostic factors of systematic treatment of acute myeloid leukemia（M4/M5 subtype）in children［J］.The Practical Journal of Cancer,2022,37(1):154-156.
［10］ ARBER DA,ORAZI A,HASSERJIAN R,et al.The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia［J］.Blood,2016,127(20):2391-2405.
［11］ ZUSHI Y,SASAKI M,MORI A,et al.Acute monocytic leukemia diagnosed by flow cytometry includes acute myeloid leukemias with weakly or faintly positive non-specific esterase staining［J］.Hematology Reports,2018,10(1)：17-22.
［12］ MATARRAZ S,ALMEIDA J,FLORES-MONTERO J,et al.Introduction to the diagnosis and classifification of monocytic-lineage leukemias by flow cytometry［J］.Cytometry Part B：Clinical Cytometry,2017,92(3):218-227.
［13］ LUCAS F,HERGOTT CB.Advances in acute myeloid leukemia classification,prognostication and monitoring by flow cytometry［J］.Clinics in Laboratory Medicine,2023,43(3):377-398.
［14］ BARROW AD,TROWSDALE J.The extended human leukocyte receptor complex:Diverse ways of modulating immune responses［J］.Immunological Reviews,2008，224（1）:98-123.
［15］ DAERON M,JAEGER S,DU PL,et al.Immunoreceptor tyrosine-based inhibition motifs:A quest in the past and future［J］.Immunological Reviews,2008,224（1）:11-43.
［16］ KANG X,KIM J,DENG M,et al.Inhibitory leukocyte immunoglobulin-like receptors:Immune checkpoint proteins and tumor sustaining factors［J］.Cell Cycle,2016,151(1):25-40.
［17］ FANGER NA,COSMAN D,PETERSON L,et al.The MHC class I binding proteins LIR-1 and LIR-2 inhibit Fc receptor-mediated signaling in monocytes［J］.European Journal of Immunology,1998,28(11):3423-3434.
［18］ CHURCHILL HRO,FUDA FS,XU J,et al.Leukocyte immunoglobulin-like receptor B1 and B4 (LILRB1 and LILRB4):Highly sensitive and specific markers of acute myeloid leukemia with monocytic differentiation［J］.Cytometry B Clinical Cytometry,2021,100(4):1-12.
［19］ CHOSH S,SHINDE SC,KUMARAN GS,et al.Haematologic and immunopheotypic profile of acute myeloid leukemia:An experience of tata memorial hospital［J］.Indian J Cancer,2003,47(2):71-76.
［20］ 王贤，夏永泉，张葵，等.CD64和CD14单核细胞相关性急性髓系白血病诊断中的意义［J］.国际检验医学杂志,2013,13(2):158-159. WANG X,XIA YQ,ZHANG K,et al.The significance of CD64 and CD14 expression in differential diagnosis of monocyte lineage involved leukemia［J］.Int J Lab Med January,2013,13(2):158-159.
［21］ MEDEIROS B,OTHUS M,FANG M,et al.Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia:the Southwest Oncology Group (SWOG) experience［J］.Blood,2010,116(13):2224-2228.

Memo

Memo:
海南省自然科学基金资助项目（编号：821RC1113)；海南省卫生健康行业科研项目（编号：21A200177）；海南省临床医学中心建设项目资助［编号：琼卫医函〔2022〕341号］
Last Update: 1900-01-01